Biogen price target lowered to $146 from $152 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $146 from $152 and keeps an Equal Weight rating on the shares. The company posted a Q1 beat and revised 2025 EPS guidance to reflect the Stoke upfront payment and foreign exchange benefits, the analyst tells investors. The firm updated its model for Q1 trends and commentary and also rolled forward the discount period it uses to derive its price target the analyst noted.